Vera Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Vera Therapeutics, Inc. on May 21, 2026. The record date for the meeting was March 24, 2026, with 71,713,905 shares of Class A common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders voted on three proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Three Class II Directors were elected to serve until the 2029 Annual Meeting.
- Michael M. Morrisey, Ph.D.: 45,288,710 votes For; 13,814,671 votes Withheld.
- Patrick G. Enright: 54,697,296 votes For; 4,406,085 votes Withheld.
- James R. Meyers: 58,946,269 votes For; 157,112 votes Withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- For: 61,834,842
- Against: 44,710
- Abstain: 87,298
- Proposal 3 (Advisory Vote on Executive Compensation): Stockholders approved the compensation for named executive officers on an advisory basis.
- For: 56,585,568
- Against: 2,433,537
- Abstain: 84,276
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. Detailed descriptions of the proposals are referenced in the Proxy Statement filed on April 9, 2026.
Key Facts for Investor Verification
- Verify the specific terms of the director elections and the tenure of the newly elected Class II Directors.
- Review the definitive Proxy Statement (filed April 9, 2026) for details on executive compensation and auditor fees.
- Confirm the total number of shares outstanding and the percentage of votes withheld for Michael M. Morrisey, Ph.D., which was notably higher than for other nominees.
- Check subsequent filings for the company's financial performance for the fiscal year ending December 31, 2026, as this 8-K contains no financial data.